Medical network - June 15 recently, American FDA for "abuse will affect public health reasons," asked drugmakers Endo Pharmaceuticals company production must be potent opioid analgesics ketone hydroxyl morphine relievers - (Opana ER).
Opana ER was approved for the first time in 2006 to treat moderate to severe pain in the long-term, all-weather opioid painkiller. In 2012, Endo retuned Opana ER's formula, aimed at making drugs resistant to physical and chemical manipulation of nasal or injection abuse. However, more risk information has forced the FDA to take steps to remove the reformulated Opana ER. In fact, Opana ER has been on a downward spiral since the launch of the new formula in 2012, which led to a big inflection point for Opana ER sales.
Sales of hydroxymorphone foreign markets
Another commonly abused opioid drug is OxyContin. According to China's pharmaceutical industry information center of CPM statistics, in recent years, though, OxyContin sales trends show instability in the foreign market, but it is still difficult to suppress the growth of in the domestic market.
The hydroxycosterone sales are in the home market
The overall market is cooling
In recent years, the overall market for pain-relieving drugs has been somewhat weak, according to the PDB database, a Chinese medical industry information center. In 2015, more than 70 percent of the sales of analgesic products were negative.
2015 global pain drug sales (millions of dollars)
Global sales of painkillers in 2015 changed year-on-year
From the analysis of the market in China's key city hospitals, the year-on-year growth rate of analgesic drug sales has declined. The best growth in 2016 was for him, with the market share of gizzine to win.
Analysis of sales growth of analgesics in China's key urban hospitals
The market for the market for pain medicine in 2016
The number of new drug approvals has tightened
The decline in the number of new drug approvals has also seen the market start to "calm down". A total of 50 pain-relieving drugs were listed in 2016, down 29.5% from 2015. Only 17 products were approved in the first quarter of 2017, and the overall number is expected to be the same as in 2016.
In recent years, there have been global approvals for the analgesic drugs
In the future, under the trend of analgesic drugs to strengthen the management, the market will be more and more play to the role of the "screen sour", the clinical analgesic effect is good, the side effects of low product demand growth, and drug abuse will eventually be betrayed by the environment.
|
